Literature DB >> 23603808

Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Fabio Di Domenico1, Raffaella Coccia, Annalisa Cocciolo, M Paul Murphy, Giovanna Cenini, Elizabeth Head, D Allan Butterfield, Alessandra Giorgi, Maria Eugenia Schinina, Cesare Mancuso, Chiara Cini, Marzia Perluigi.   

Abstract

DS is the most frequent genetic cause of intellectual disability characterized by the anomalous presence of three copies of chromosome 21. One of the peculiar features of DS is the onset of Alzheimer's disease neuropathology after the age of 40years characterized by deposition of senile plaques and neurofibrillary tangles. Growing studies demonstrated that increased oxidative damage, accumulation of unfolded/damaged protein aggregates and dysfunction of intracellular degradative system are key players in neurodegenerative processes. In this study, redox proteomics approach was used to analyze the frontal cortex from DS subjects under the age of 40 compared with age-matched controls, and proteins found to be increasingly carbonylated were identified. Interestingly, our results showed that oxidative damage targets specifically different components of the intracellular quality control system such as GRP78, UCH-L1, V0-ATPase, cathepsin D and GFAP that couples with decreased activity of the proteasome and autophagosome formation observed. We also reported a slight but consistent increase of Aβ 1-42 SDS- and PBS-soluble form and tau phosphorylation in DS versus CTR. We suggest that disturbance in the proteostasis network could contribute to the accumulation of protein aggregates, such as amyloid deposits and NFTs, which occur very early in DS. It is likely that a sub-optimal functioning of degradative systems occur in DS neurons, which in turn provide the basis for further accumulation of toxic protein aggregates. The results of this study suggest that oxidation of protein members of the proteostatis network is an early event in DS and might contribute to neurodegenerative phenomena.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603808      PMCID: PMC3940071          DOI: 10.1016/j.bbadis.2013.04.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  85 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

Review 2.  Down syndrome and beta-amyloid deposition.

Authors:  Elizabeth Head; Ira T Lott
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

3.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Nicole B Terio; Corrinne M Peterhoff; Robert Durham; Marc Mercken; Pankaj D Mehta; Joseph Buxbaum; Vahram Haroutunian; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

4.  The unfolded protein response and proteostasis in Alzheimer disease: preferential activation of autophagy by endoplasmic reticulum stress.

Authors:  Wiep Scheper; Diana A T Nijholt; Jeroen J M Hoozemans
Journal:  Autophagy       Date:  2011-08-01       Impact factor: 16.016

Review 5.  Degradation of oxidized proteins in mammalian cells.

Authors:  T Grune; T Reinheckel; K J Davies
Journal:  FASEB J       Date:  1997-06       Impact factor: 5.191

6.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

Review 7.  Autophagy in aging and Alzheimer's disease: pathologic or protective?

Authors:  Aaron Barnett; Gregory J Brewer
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.

Authors:  Joungil Choi; Allan I Levey; Susan T Weintraub; Howard D Rees; Marla Gearing; Lih-Shen Chin; Lian Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

Review 9.  Protein misfolding and neurodegeneration.

Authors:  Claudio Soto; Lisbell D Estrada
Journal:  Arch Neurol       Date:  2008-02

10.  The topography of plaques and tangles in Down's syndrome patients of different ages.

Authors:  D M Mann; P O Yates; B Marcyniuk; C R Ravindra
Journal:  Neuropathol Appl Neurobiol       Date:  1986 Sep-Oct       Impact factor: 8.090

View more
  49 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

Review 3.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

4.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 5.  The fine-tuning of proteolytic pathways in Alzheimer's disease.

Authors:  Valentina Cecarini; Laura Bonfili; Massimiliano Cuccioloni; Matteo Mozzicafreddo; Mauro Angeletti; Jeffrey N Keller; Anna Maria Eleuteri
Journal:  Cell Mol Life Sci       Date:  2016-04-27       Impact factor: 9.261

Review 6.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 7.  The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

Authors:  Eugenio Barone; Fabio Di Domenico; Cesare Mancuso; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2013-10-02       Impact factor: 5.996

Review 8.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

Review 9.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 10.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.